Melanotan I (also known as Afamelanotide or [Nle4, D-Phe7]-α-MSH) is a synthetic peptide analog of endogenous alpha-melanocyte-stimulating hormone (α-MSH). In preclinical models, it functions as a potent, non-selective melanocortin receptor agonist, primarily evaluated for its binding affinity at the MC1R receptor site and its downstream activation of melanogenesis within laboratory research assays.
Melanotan I (also known as Afamelanotide or [Nle4, D-Phe7]-α-MSH) is a synthetic peptide analog of endogenous alpha-melanocyte-stimulating hormone (α-MSH). In preclinical models, it functions as a potent, non-selective melanocortin receptor agonist, primarily evaluated for its binding affinity at the MC1R receptor site and its downstream activation of melanogenesis within laboratory research assays.
Melanotan I is a synthetic tridecapeptide engineered to mimic and enhance the biological signaling of native alpha-melanocyte-stimulating hormone (α-MSH). endogenous α-MSH plays a central regulatory role in the melanocortin system, a complex network of peptide hormones, transmembrane G-protein coupled receptors (GPCRs), and intracellular secondary messengers. Researchers investigating skin biology, photoprotection, and pigmentation pathways frequently utilize Melanotan I as a stable reference agonist to probe melanocortin receptor function.
The melanocortin receptor family consists of five distinct subtypes (MC1R through MC5R), each coupled to stimulatory G-proteins ($G_s$) that activate adenylyl cyclase upon ligand binding. Melanotan I exhibits high binding affinity across multiple melanocortin subtypes, with a pronounced operational potency at MC1R. In vitro and ex vivo investigations demonstrate that ligand engagement at MC1R initiates an intracellular cascade leading to elevated cyclic adenosine monophosphate (cAMP) levels, activation of protein kinase A (PKA), and subsequent transcription of tyrosinase—the rate-limiting enzyme in melanin synthesis.
Because native α-MSH possesses a brief biological half-life due to rapid enzymatic degradation by serum proteases, structural modifications were introduced to create Melanotan I. These amino acid substitutions significantly increase the peptide's resistance to proteolytic cleavage and enhance its receptor binding duration, making it a valuable tool for comparative cell culture assays and animal studies within the broader library of research peptides.
The primary sequence of endogenous α-MSH is Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2. Melanotan I modifies this baseline sequence at two specific positions: Norleucine (Nle) replaces Methionine at position 4, and D-Phenylalanine (D-Phe) replaces L-Phenylalanine at position 7. The resulting chemical formula is $C_{78}H_{111}N_{21}O_{19}$, with a molecular weight of approximately 1646.85 Da.
The substitution of Met4 with Norleucine eliminates susceptibility to oxidative degradation at the thioether side chain, stabilizing the peptide in aqueous solution. Concurrently, replacing L-Phe7 with D-Phe7 induces a structural constraint that stabilizes a beta-turn conformation crucial for receptor interaction. This conformational rigidity significantly enhances the peptide's steric fit within the binding pocket of melanocortin receptors.
These strategic modifications alter the peptide's thermodynamic stability and pharmacokinetics without compromising its structural alignment with the melanocortin signaling domain. Consequently, laboratory researchers utilize Melanotan I to examine how small structural alterations in peptide secondary architecture influence receptor activation kinetics and downstream transcriptional output.
The physiological effects observed in preclinical research involving Melanotan I stem from its differential binding profile across the melanocortin receptor family. Competitive radioligand binding assays indicate that Melanotan I binds to MC1R with nanomolar affinity ($K_i$ values typically ranging between 0.1 and 1.0 nM), while displaying varying affinity for MC3R, MC4R, and MC5R. It demonstrates negligible interaction with MC2R, which is selectively responsive to adrenocorticotropic hormone (ACTH).
Upon binding to MC1R expressed on the surface of cutaneous melanocytes, Melanotan I induces a conformational shift in the receptor that facilitates the exchange of GDP for GTP on the sub-unit of the coupled $G_s$ protein. The activated alpha sub-unit dissociates to stimulate adenylyl cyclase, converting ATP to cAMP. High intracellular cAMP concentrations activate PKA, which translocates to the nucleus to phosphorylate the cAMP response element-binding protein (CREB).
Phosphorylated CREB drives the transcription of Microphthalmia-associated Transcription Factor (MITF), the master transcriptional regulator of melanocyte development and function. MITF upregulates the expression of key melanogenic enzymes, including tyrosinase, tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT). Preclinical research models use this well-defined pathway to study the biochemical mechanisms underlying eumelanin production versus pheomelanin production.
Preclinical investigations using rodent models, organotypic skin constructs, and human melanocyte cell cultures have extensively documented the melanogenic response elicited by Melanotan I. In vitro assays demonstrate that incubation of melanocytes with Melanotan I results in dose-dependent increases in cellular tyrosinase activity and total melanin content within 48 to 72 hours of exposure.
Cellular assays further reveal that Melanotan I preferentially stimulates the synthesis of eumelanin, a dark brown/black pigment with high ultraviolet (UV) radiation absorbance capabilities, over pheomelanin, a red/yellow sulfur-containing pigment that can generate reactive oxygen species (ROS) under UV irradiation. By shifting the eumelanin-to-pheomelanin ratio, the peptide modulates the cell's intrinsic oxidative stress environment following exposure to simulated solar light.
In vivo animal studies—specifically involving non-human primates and transgenic mice—indicate that systemic or localized administration of Melanotan I increases cutaneous pigmentation independently of direct UV light exposure. Researchers analyze these models to evaluate baseline photoprotective responses, cellular DNA damage repair mechanisms (such as cyclobutane pyrimidine dimer clearance), and skin barrier responses to environmental stressors as part of broader melanocortin system research.
When designing preclinical experiments, researchers frequently compare Melanotan I against other synthetic melanocortin peptides to evaluate structural, pharmacological, and functional differences. Understanding these differences allows laboratories to select the precise tool required for their specific receptor binding or behavioral models.
Unlike Melanotan I, which maintains a linear tridecapeptide structure matching the full length of native α-MSH, Melanotan II is a cyclic heptapeptide ($Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH_2$). This cyclic structural constraint allows Melanotan II to readily cross the blood-brain barrier and bind with high affinity to central MC3R and MC4R receptors. Consequently, Melanotan II exhibits prominent central nervous system effects—such as modulation of sexual behavior and appetite suppression—in animal models, whereas Melanotan I primarily targets peripheral MC1R responses with reduced central receptor crossover.
Similarly, compounds like PT-141 (Bremelanotide)—a metabolite fragment derivative of Melanotan II—are engineered specifically for central MC3R/MC4R activation, showing minimal activity at peripheral MC1R sites. Researchers examining isolated cutaneous pigmentation mechanisms typically select Melanotan I to minimize central nervous system confounders, whereas researchers studying metabolic or neuroendocrine signaling pathways opt for cyclic analogs.
Proper handling and reconstitution protocols are essential for maintaining the structural integrity of Melanotan I during laboratory procedures. Analytical grade Melanotan I is supplied as a lyophilized (freeze-dried) powder sealed under inert gas to prevent moisture uptake and oxidative degradation during transit.
To reconstitute Melanotan I for cell culture or enzymatic assays, technicians should use sterile, non-pyrogenic Bacteriostatic Water or standard laboratory-grade phosphate-buffered saline (PBS, pH 7.4), depending on assay parameters. The diluent should be introduced gently along the internal glass wall of the vial, allowing the solvent to naturally saturate the cake. Vials should be gently swirled rather than vortexed to avoid shear-induced aggregation or denaturing of the peptide chain. For precise molarity calculations during assay setup, laboratories frequently utilize a specialized peptide reconstitution calculator.
Following reconstitution, working aliquots should be prepared to avoid repeated freeze-thaw cycles, which degrade peptide potency over time. Concentrated stock solutions are stable at 2°C to 8°C for short-term evaluation (up to 30 days) or at -20°C to -80°C for extended storage across multi-phase experimental designs.
Rigorous analytical verification is paramount when procuring research-grade peptides. Impurities such as truncated sequences, residual trifluoroacetic acid (TFA) salts, heavy metals, or organic solvents can disrupt cell viability assays, alter receptor binding kinetics, and introduce unpredictable variables into experimental data.
PX1 Research enforces strict quality assurance criteria for every production lot of Melanotan I. Each batch undergoes rigorous testing via High-Performance Liquid Chromatography (RP-HPLC) paired with Mass Spectrometry (MS) to confirm sequence identity, molecular mass verification, and chemical purity. A lot-specific Certificate of Analysis (COA) detailing these metrics is generated for every batch.
Key quality standards maintained by PX1 Research include:
• Chemical Purity: $\ge 98.0\%$ verified via RP-HPLC peak area integration. • Mass Identification: Single major peak on Electrospray Ionization Mass Spectrometry (ESI-MS) matching the theoretical molecular weight (1646.85 Da). • Endotoxin Testing: Quantitative Chromogenic LAL assay ensuring endotoxin levels are maintained below strict laboratory limits ($<0.05 \text{ EU/mg}$). • Manufacturing Control: Produced in state-of-the-art US-based facilities operating under cGMP-compliant standards and verified by an independent ISO 17025 accredited testing laboratory.
Reliable baseline data requires consistent batch-to-batch chemical stability. PX1 Research serves as a trusted vendor for academic institutions, biotechnology firms, and contract research organizations requiring verified compounds for preclinical studies.
All products ship directly from centralized warehouses located in California and Arizona, with same-day shipping applied to all orders placed Monday through Friday before 12:00 PM PST. This rapid fulfillment infrastructure minimizes transit times and temperature fluctuations, preserving compound stability.
Laboratories conducting high-throughput screening or multi-phase rodent trials can secure volume-discounted materials and dedicated account support through the PX1 Research wholesale lab account portal. All peptides provided by PX1 Research are strictly designated for in vitro, analytical, and preclinical research applications.
What is the primary mechanism of action for Melanotan I in research models?
Melanotan I functions as a full synthetic agonist at melanocortin receptors, displaying high selectivity for the MC1R subtype. Upon binding, it stimulates adenylyl cyclase activity, increasing intracellular cAMP, activating PKA, and upregulating MITF expression, which drives the transcription of melanogenic enzymes like tyrosinase.
How does Melanotan I differ structurally from native alpha-MSH?
Melanotan I modifies native α-MSH by replacing Methionine at position 4 with Norleucine (Nle4) and L-Phenylalanine at position 7 with D-Phenylalanine (D-Phe7). These substitutions increase resistance to enzymatic cleavage and stabilize its binding conformation.
What is the difference between Melanotan I and Melanotan II?
Melanotan I is a linear 13-amino acid peptide focused primarily on peripheral MC1R activation, while Melanotan II is a cyclic 7-amino acid peptide that easily crosses the blood-brain barrier and strongly activates central MC3R and MC4R receptors.
How should lyophilized Melanotan I be stored upon delivery?
Lyophilized Melanotan I powder should be stored in a dry, dark environment at -20°C for long-term stability. Avoid exposure to light, moisture, and elevated ambient temperatures.
What diluent is recommended for reconstituting Melanotan I for laboratory assays?
For standard laboratory assays, sterile Bacteriostatic Water or sterile phosphate-buffered saline (PBS, pH 7.4) is typically recommended depending on cell culture protocols and solubility requirements.
How does PX1 Research verify the purity of its Melanotan I batches?
Every lot of Melanotan I undergoes reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry (MS) to verify structural identity and guarantee a purity level of at least 98.0%. Lot-specific COAs are available for every purchase.
What are the endotoxin thresholds for PX1 Research compounds?
PX1 Research tests every batch using chromogenic LAL assays to ensure endotoxin levels remain below strictly controlled limits (<0.05 EU/mg), ensuring suitability for sensitive cell assays.
Can Melanotan I be purchased for non-laboratory or personal use?
No. Melanotan I and all other compounds supplied by PX1 Research are strictly designated for laboratory research, in vitro experimentation, and preclinical scientific study. They are not for human or animal consumption.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.